UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1392-3
Program Prior Authorization/Notification
Medication Radicava ORS® (edaravone)
P&T Approval Date 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Radicava ORS is indicated for the treatment of amyotrophic lateral sclerosis (ALS).1
2. Coverage Criteriaa:
A. Initial Authorization
1. Radicava ORS will be approved based upon the following criterion:
a. Diagnosis of amyotrophic lateral sclerosis (ALS)
Authorization will be issued for 12 months.
B. Reauthorization
1. Radicava ORS will be approved based upon the following criterion:
a. Documentation of positive clinical response to Radicava ORS therapy.
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class
• Supply limits may be in place.
4. References:
1. Radicava ORS [package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation.
May 2022.
© 2024 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification - Radicava ORS® (edaravone)
Change Control
7/2022 New program.
7/2023 Annual review with no changes to the coverage criteria.
7/2024 Annual review. Updated initial authorization and reauthorization to 12
months.
© 2024 UnitedHealthcare Services, Inc.
2